Tag Archives: act

Video: 3 Big Cap Biotechs Bucking Market Correction

Though the market is in a correction, there are several big cap medical stocks bucking the downtrend. IBD TV’s Alissa Williams breaks down the top three: Gilead Sciences (GILD), Actavis (ACT) and Alexion Pharmaceuticals (ALXN). Follow Alissa Williams on Twitter: @IBD_AWilliams .

Actavis Expands Antibiotics Presence With Durata Buy

Specialty-drug giant Actavis (ACT) said Monday that it’s acquiring biotech startup Durata Therapeutics for $675 million in cash, sending Durata’s stock up more than 70% to a new high of 24.25 on the stock market today . Actavis’ stock was flat in morning trading. Durata Therapeutics’ (DRTX) lone product, Dalvance, is an antibiotic for acute bacterial skin infections, dosed intravenously twice over two weeks. It was approved in the U.S. in May and

Valeant Ends Prince Charming Act; Allergan Hopes Rise

Valeant Pharmaceuticals (VRX) shares popped on upbeat guidance and as the addition of Actavis (ACT) to the Allergan-Valeant-Salix triangle lifted Valeant’s chances for an Allergan takeover. Valeant said it expects to beat third-quarter analyst views on revenue and its own cash EPS guidance when it reports on Oct. 20. It also sees same-store organic growth exceeding 15% in Q3, with its Bausch + Lomb segment delivering more than 10% organic growth.